Dr Reddys Laboratories becomes largest Indian Pharma company in Russia

Dr. Reddys Laboratories Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 500124 | NSE: DRREDDY

19 Mar 2009 Evaluate

Dr Reddys Laboratories has recorded 24% growth in revenues in Russia / CIS region to US$ 150 million in the eleven months ended February 2009. This is based on invoicing as per average foreign currency rates for this period, excluding any impact due to cash flow hedging. In the process, Dr Reddys has become the largest Indian pharmaceutical company in Russia, and is also boasting of as the fastest growing International branded generic company by volume.

As per Russian Market research firm Pharmexpert, Dr Reddys is ranked 7^th amongst generic companies in Russia as of February 2009. Dr Reddys top four brands in Russian Market are Omez, Nisa, Ketorol, Cirpolet and Pharmexpert has ranked them as No. 1 in their respective molecular segment. crack crack

Peers

Company Name	CMP
Sun Pharma. Inds.	1842.00
Dr. Reddys Labs.	1161.00
Cipla	1365.00
Lupin	2096.00
Zydus Lifesciences	1119.50
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.